UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

May 2017

UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours

Results from a published multicenter study

The results from a German multicenter study were published in the latest issue of Tumor Biology. Principal investigator was  Dr Thorsten Ecke at the Department of Urology, HELIOS Hospital, Bad Saarow.

Urine samples were analyzed with UBC® Rapid POC test and results were determined quantitatively with a reader.

Bladder cancer is one of the most costly cancer diseases, affecting around 2500 persons yearly in Sweden.

The most common method for detection of bladder cancer and for the assessment of recurrence is cystoscopy, a procedure in which an optic fiber is used for examination of the bladder.

The Swedish company IDL Biotech AB has developed a complementary test to cystoscopy – UBC® Rapid, especially useful for detection of high grade bladder cancer.

The test is already clinically documented and is in routine use in Germany.

The combination of UBC® Rapid with an objective POC-reader can enable improved risk stratification.

The new study demonstrated a very high sensitivity (71%) and specificity (94%)for high grade tumors. For patients with cancer in situ (CIS), the sensitivity was even higher (87%). The authors conclude that UBC® Rapid should be added in the diagnostics of high grade tumors and especially for CIS patients.

IDL to strengthen global sales

IDL Biotech today announced that they are strengthening their global Sales and Marketing team. Martyn Eales has been named Senior Vice President of Global Sales and Marie Torstensson has been named Marketing Manager. Together they will lead the effort to increase international sales.

Patent approved in Europe

During 2015 the patent ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.

IDL Biotech

Skip this intro